Effects of Acute Colchicine Administration Prior to Percutaneous Coronary Intervention: COLCHICINE-PCI Randomized Trial.


Journal

Circulation. Cardiovascular interventions
ISSN: 1941-7632
Titre abrégé: Circ Cardiovasc Interv
Pays: United States
ID NLM: 101499602

Informations de publication

Date de publication:
04 2020
Historique:
entrez: 17 4 2020
pubmed: 17 4 2020
medline: 11 11 2020
Statut: ppublish

Résumé

Vascular injury and inflammation during percutaneous coronary intervention (PCI) are associated with increased risk of post-PCI adverse outcomes. Colchicine decreases neutrophil recruitment to sites of vascular injury. The anti-inflammatory effects of acute colchicine administration before PCI on subsequent myocardial injury are unknown. In a prospective, single-site trial, subjects referred for possible PCI (n=714) were randomized to acute preprocedural oral administration of colchicine 1.8 mg or placebo. Among the 400 subjects who underwent PCI, the primary outcome of PCI-related myocardial injury did not differ between colchicine (n=206) and placebo (n=194) groups (57.3% versus 64.2%, Acute preprocedural administration of colchicine attenuated the increase in interleukin-6 and high-sensitivity C-reactive protein concentrations after PCI when compared with placebo but did not lower the risk of PCI-related myocardial injury. Registration: URL: https://www.clinicaltrials.gov; Unique Identifiers: NCT02594111, NCT01709981.

Sections du résumé

BACKGROUND
Vascular injury and inflammation during percutaneous coronary intervention (PCI) are associated with increased risk of post-PCI adverse outcomes. Colchicine decreases neutrophil recruitment to sites of vascular injury. The anti-inflammatory effects of acute colchicine administration before PCI on subsequent myocardial injury are unknown.
METHODS
In a prospective, single-site trial, subjects referred for possible PCI (n=714) were randomized to acute preprocedural oral administration of colchicine 1.8 mg or placebo.
RESULTS
Among the 400 subjects who underwent PCI, the primary outcome of PCI-related myocardial injury did not differ between colchicine (n=206) and placebo (n=194) groups (57.3% versus 64.2%,
CONCLUSIONS
Acute preprocedural administration of colchicine attenuated the increase in interleukin-6 and high-sensitivity C-reactive protein concentrations after PCI when compared with placebo but did not lower the risk of PCI-related myocardial injury. Registration: URL: https://www.clinicaltrials.gov; Unique Identifiers: NCT02594111, NCT01709981.

Identifiants

pubmed: 32295417
doi: 10.1161/CIRCINTERVENTIONS.119.008717
pmc: PMC7169992
mid: NIHMS1567455
doi:

Substances chimiques

Anti-Inflammatory Agents 0
Biomarkers 0
IL6 protein, human 0
Inflammation Mediators 0
Interleukin-6 0
C-Reactive Protein 9007-41-4
Colchicine SML2Y3J35T

Banques de données

ClinicalTrials.gov
['NCT02594111', 'NCT01709981']

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e008717

Subventions

Organisme : CSRD VA
ID : IK2 CX001074
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016087
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

Mol Cell Biochem. 2003 Jul;249(1-2):67-73
pubmed: 12956400
Nature. 2006 Mar 9;440(7081):237-41
pubmed: 16407889
J Am Coll Cardiol. 2006 Oct 17;48(8):1560-6
pubmed: 17045888
J Clin Invest. 1995 Aug;96(2):994-1002
pubmed: 7543498
J Leukoc Biol. 2013 Nov;94(5):1091-6
pubmed: 23901122
Clin Ther. 2006 Jan;28(1):26-35
pubmed: 16490577
J Am Coll Cardiol. 1999 Nov 1;34(5):1512-21
pubmed: 10551701
Inflammation. 2016 Feb;39(1):182-189
pubmed: 26318864
Am J Cardiol. 2002 Feb 15;89(4):372-6
pubmed: 11835913
J Am Coll Cardiol. 2009 Aug 4;54(6):558-65
pubmed: 19643320
J Rheumatol. 2007 Jul;34(7):1540-4
pubmed: 17610314
Am J Med Sci. 2016 Sep;352(3):261-6
pubmed: 27650230
J Cardiovasc Med (Hagerstown). 2010 Nov;11(11):795-800
pubmed: 20613550
J Am Heart Assoc. 2015 Aug 24;4(8):e002128
pubmed: 26304941
Proc Natl Acad Sci U S A. 1977 Aug;74(8):3404-8
pubmed: 198784
Ren Fail. 2015 Aug;37(7):1122-5
pubmed: 26067744
J Am Coll Cardiol. 2007 Mar 27;49(12):1272-8
pubmed: 17394957
J Am Coll Cardiol. 2013 Apr 23;61(16):1679-85
pubmed: 23500260
Semin Arthritis Rheum. 2009 Jun;38(6):411-9
pubmed: 18973929
Circulation. 2012 Oct 16;126(16):2020-35
pubmed: 22923432
J Am Coll Cardiol. 2004 Oct 6;44(7):1408-14
pubmed: 15464320
Arterioscler Thromb Vasc Biol. 2000 Dec;20(12):2553-8
pubmed: 11116052
J Thromb Thrombolysis. 2011 Jan;31(1):92-8
pubmed: 20373128
J Am Coll Cardiol. 2001 Mar 1;37(3):839-46
pubmed: 11693760
Atherosclerosis. 2008 Mar;197(1):368-74
pubmed: 17640648
J Intern Med. 2007 Dec;262(6):659-67
pubmed: 17927738
J Thromb Thrombolysis. 2003 Feb;15(1):25-31
pubmed: 14574073
Arthritis Rheum. 2010 Apr;62(4):1060-8
pubmed: 20131255
AIDS. 2010 Jun 1;24(9):1377-80
pubmed: 20559042
J Am Coll Cardiol. 2013 Oct 22;62(17):1563-70
pubmed: 24135581
Int J Immunopathol Pharmacol. 2004 May-Aug;17(2):165-70
pubmed: 15171817
J Am Coll Cardiol. 2009 Dec 1;54(23):2157-63
pubmed: 19664895
J Rheumatol. 2012 Jul;39(7):1458-64
pubmed: 22660810
Circulation. 2004 Aug 10;110(6):674-8
pubmed: 15277322
Basic Res Cardiol. 2005 Sep;100(5):413-21
pubmed: 15944806
Scand Cardiovasc J. 2007 Jun;41(3):149-54
pubmed: 17487763
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
J Am Coll Cardiol. 1996 Nov 1;28(5):1127-33
pubmed: 8890805
JAMA. 2011 May 11;305(18):1882-9
pubmed: 21558519
Am J Cardiol. 2007 Mar 15;99(6):805-7
pubmed: 17350370
Atherosclerosis. 2005 Oct;182(2):341-8
pubmed: 16159607
Circ Cardiovasc Interv. 2017 Sep;10(9):
pubmed: 28916600
Arch Intern Med. 2012 Mar 26;172(6):502-8
pubmed: 22371874
Arterioscler Thromb Vasc Biol. 1996 Oct;16(10):1312-8
pubmed: 8857930
J Am Coll Cardiol. 2013 Jan 29;61(4):404-410
pubmed: 23265346

Auteurs

Binita Shah (B)

Section of Cardiology, Department of Medicine (B.S., J.D.L., N.R.S.), VA New York Harbor Health Care System.
Division of Cardiology, Department of Medicine (B.S., J.D.L., N.R.S., F.F., N.R., N.M.K., S.D.K.), New York University School of Medicine.

Michael Pillinger (M)

Section of Rheumatology, Department of Medicine (M.P.), VA New York Harbor Health Care System.
Division of Rheumatology, Department of Medicine (M.P., B.C.), New York University School of Medicine.

Hua Zhong (H)

Division of Biostatistics, Department of Population Health (H.Z., Y.X.), New York University School of Medicine.

Bruce Cronstein (B)

Division of Rheumatology, Department of Medicine (M.P., B.C.), New York University School of Medicine.

Yuhe Xia (Y)

Division of Biostatistics, Department of Population Health (H.Z., Y.X.), New York University School of Medicine.

Jeffrey D Lorin (JD)

Section of Cardiology, Department of Medicine (B.S., J.D.L., N.R.S.), VA New York Harbor Health Care System.
Division of Cardiology, Department of Medicine (B.S., J.D.L., N.R.S., F.F., N.R., N.M.K., S.D.K.), New York University School of Medicine.

Nathaniel R Smilowitz (NR)

Section of Cardiology, Department of Medicine (B.S., J.D.L., N.R.S.), VA New York Harbor Health Care System.
Division of Cardiology, Department of Medicine (B.S., J.D.L., N.R.S., F.F., N.R., N.M.K., S.D.K.), New York University School of Medicine.

Frederick Feit (F)

Division of Cardiology, Department of Medicine (B.S., J.D.L., N.R.S., F.F., N.R., N.M.K., S.D.K.), New York University School of Medicine.

Nicole Ratnapala (N)

Division of Cardiology, Department of Medicine (B.S., J.D.L., N.R.S., F.F., N.R., N.M.K., S.D.K.), New York University School of Medicine.

Norma M Keller (NM)

Division of Cardiology, Department of Medicine (B.S., J.D.L., N.R.S., F.F., N.R., N.M.K., S.D.K.), New York University School of Medicine.

Stuart D Katz (SD)

Division of Cardiology, Department of Medicine (B.S., J.D.L., N.R.S., F.F., N.R., N.M.K., S.D.K.), New York University School of Medicine.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH